Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Clinical trial NCT05984199 · TERMINATED

Trial details

NCT number: NCT05984199
Sponsor: Vor Biopharma
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute

Start date: 2023-12-11
Primary completion: 2025-05-28
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.